MBQ-Pharma targets Rac and CDC42 as key targets for tumor growth inhibition and removal of pre-existing metastasis. MBQ-167 is a first-in-class nanomolar IC50 inhibitor for Rac and CDC42 and has been shown in mouse tumor models to inhibit tumor growth and to reverse advanced metastasis. MBQ-167 has also been shown to have no toxicity findings in rats and dogs through GLP studies and in Safety Pharmacology studies. The IND for MBQ-167 is scheduled by the end of 2021.

MBQ Pharma

Jose F. Rodriguez-Orengo

This department sets the strategic direction and oversees the overall operations of the organization.

MBQ Pharma

Org chart

Teams

Executive Leadership

Offices

MBQ Pharma

Org chart

Teams

Executive Leadership

Offices

Related companies